Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 1803 for “"GENE THERAPY"”.
-
Telomerase Directed Gene Therapy
… is the transcription of the telomerase sub-unit genes. In the present study, I describe the development of a transcriptionally directed cytotoxic gene therapy approach targeted against telomerase positive cancer cells. Transfection experiments using fragments of the human telomerase RNA component …
-
Development of a Novel Gene Therapy & Investigation of Synthetic Gene Therapy Delivery Systems
… type R9 is caused by a mutation in the FKRP gene, that encodes one of various enzymes that glycosylates the muscle membrane protein dystroglycan. The result is muscle degeneration and weakness, and palliative care is presently the only available treatment for dystroglycanopathy patients. We …
-
Gene therapy for methylmalonic aciduria.
… of a LV vector that expresses human MCM transgene in MCM knockout fibroblasts and a MMA affected, mut -/- muth2, murine model. In the first study, a self-inactivating LV vector that expressed human MCM, HIV- 1SDmEF1αhMCM, was constructed and transduced into MCM knockout fibroblasts. Normal …
-
Gene therapy for Athabascan SCID
… joining (V(D)J) recombination. Mutations in the gene encoding Artemis result in a radiationsensitive form of severe combined immunodeficiency (SCID) found at a high incidence in Athabascan-speaking Native Americans (SCID-A) and characterized by the absence of mature B and T lymphocytes. Early …
-
Suppressor tRNA mediated gene therapy
<p>Nearly one third of all human genetic diseases are caused due to nonsense mutations that can result in truncated proteins. Nonsense suppressor tRNAs (NSTs) were proposed as valuable tools for gene therapy of genetic diseases caused by premature termination codons (PTCs). Although various …
-
Gene Therapy for Mucopolysaccharidosis Type II
… treatment for MPS II is enzyme replacement therapy (ERT, Elaprase®); allogeneic hematopoietic stem cell transplantation (HSCT) is conducted on a trial basis. ERT is expensive, time consuming, and administered IDS enzyme does not readily cross the blood brain barrier, leaving the neurological …
-
Immunological responses to retinal gene therapy
… in adeno-associated virus (AAV)–mediated retinal gene therapy trials have restricted the use of high vector doses and impeded the ability to enhance therapeutic efficacy. Characterising the nature of this response, and devising methods to overcome it, are thus becoming increasingly important in …
-
Optogenetic gene therapy for vision restoration
<p>Inherited retinal dystrophies are a heterogeneous group of retinal diseases that often lead to blindness. The diverse range of causative gene mutations poses great challenges to developing therapies to improve the vision of affected people. One technique being investigated is optogenetics for …
-
HIV Transmission, Entry, and Gene Therapy
… drugs and provided insights into viral pathogenesis. One critical question is whether we can further exploit our knowledge of the HIV entry process to develop an effective therapeutic vaccine. To do this, we need to better understand HIV-1 transmission, which may reveal viral properties that …
-
Multifunctional bioreducible nanoparticles for gene therapy
Gene therapy is a promising therapeutic strategy to treat diseases caused by single or multiple gene mutations. Non-viral gene delivery vectors exhibit many advantages over viral vectors, including enhanced safety, versatility in choosing different types of therapeutic nucleic acids, and ease of …
-
Neuroprotection gene therapy in retinal degeneration
<p>Retinal degenerative disease, which includes age-related macular degeneration and retinitis pigmentosa, is the main cause of blindness in developed countries. Degeneration of the retinal pigment epithelium (RPE) and photoreceptor cells through apoptosis is believed to be the main mechanism of …
-
Recombinant AAV Gene Therapy and Delivery
… form of dementia which can occur as a result of genetic mutations in the genes encoding presenilin 1, presenilin 2, or amyloid precursor protein (APP). These genetic alterations can accelerate the pathological characteristics of AD, including the formation of extracellular neuritic plaques …
-
Novel Approaches to Thalassaemia Gene Therapy
The haemoglobinopathies are the most prevalent genetically inherited disorders worldwide. Gene therapy for p-thalassaemia is particularly challenging given the requirement for high p-globin chain production in a lineage-specific manner. Advances in lentiviral vector (LV) technology, together with …
-
Hyperthermia induced interleukin-12 gene therapy
Cytokine genes are the most widely and extensively studied immunostimulatory agents in cancer gene therapy. In several studies, interleukin-12 (IL-12) was found to be the most effective cytokine in inducing the eradication of experimental tumors, preventing development of metastases and eliciting …
-
Gene manipulations for cancer gene therapy
Tumor cells can be modified with cytokine genes such as the Interleukin-2 (IL-2) gene. The levels of IL-2 expressed are critical for successful treatment. We have tried to achieve higher levels of IL-2 than those currently available by conventional plasmids. Use of a transcriptional activator, e.g; …
-
T cell gene therapy in vascular pathology
… results of this thesis indicate that the use of genetically modified T cells could be a viable approach in the treatment of inflammatory disorders.
-
Retrovirus-mediated Gene Therapy For Farber Disease
… consists of symptomatic supportive care and allogeneic bone marrow transplantation (BMT). However, BMT has shown limited success. Gene therapy has previously been shown to be a promising treatment strategy for monogenetic diseases and has the potential to treat the underlying cause of the …
-
Gene Therapy for Endothelial Progenitor Cell Dysfunction
Endothelial progenitor cells (EPCs) have reduced neovascularization capacity in the context of coronary artery disease (CAD) or cardiac risk factors (RFs). Since, endothelial NO synthase (eNOS) is critical to normal EPC function, we hypothesized that bone marrow cells (BMCs) from rats with RFs and …
Page 1 of 91